An assessment of clinical outcomes of medication abortion without pretreatment ultrasonography in Planned Parenthood, United States, 2020

An assessment of clinical outcomes of medication abortion without pretreatment ultrasonography in Planned Parenthood, United States, 2020–2021

Published:2024-08 Issue: Volume:136 Page:110469
ISSN:0010-7824
Container-title:Contraception
language:en
Short-container-title:Contraception

Author:

Simons Hannah R.,Diemert Sarah,Passman Rebecca,Dean Gillian

Publisher

Elsevier BV

Reference20 articles.

1. Medical management of first-trimester abortion;Bartz;Contraception,2014

2. National Abortion Federation. Clinical Policy Guidelines for Abortion Care © 2018. https://5aa1b2xfmfh2e2mk03kk8rsx-wpengine.netdna-ssl.com/wp-content/uploads/2018_CPGs.pdf (accessed October 26, 2019).

3. U.S. Food & Drug Administration. Mifeprex (mifepristone) information. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/mifeprex-mifepristone-information (accessed October 26, 2019).

4. Food and Drug Administration. MIFEPREX (mifepristone) tablets label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf (accessed October 26, 2019).

5. Planned Parenthood Federation of America. Medical standards and guidelines; 2022.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No test medical abortion – a review of the evidence on selective use of preabortion testing;Current Opinion in Obstetrics & Gynecology;2024-08-12

2. Clinical and service delivery outcomes following medication abortion provided with or without pretreatment ultrasound or pelvic examination: An updated comparative analysis;Contraception;2024-07